SCHEDULE: T. Rowe Price Updates Stake in Repligen Corp

T. Rowe Price Associates, Inc. has filed an amendment to its Schedule 13G, reporting its beneficial ownership of Repligen Corp. common stock as of June 30, 2026.

Summary

• T. Rowe Price Associates, Inc. has filed an amendment (Amendment No. 8) to its Schedule 13G filing.
• The filing pertains to the beneficial ownership of common stock of Repligen Corp.
• The date of the event requiring this filing is June 30, 2026.
• T. Rowe Price Associates, Inc. is identified as an investment adviser.
• The reporting entity beneficially owns 1,751,887 shares of Repligen Corp. common stock.
• This represents 3.1% of the class of securities.
• T. Rowe Price Associates, Inc. has sole voting power over 1,744,549 shares and sole dispositive power over 1,751,887 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily an update on beneficial ownership by an institutional investor, with no significant new strategic or financial information.

Positives

• T. Rowe Price Associates, Inc. continues to hold a significant stake in Repligen Corp., indicating ongoing confidence.
• The filing confirms T. Rowe Price Associates, Inc.'s role as a substantial institutional investor.

Negatives

• No new financial performance data or strategic initiatives are disclosed in this filing.

Risks

• The filing does not contain specific risk factors related to Repligen Corp.'s business operations or market conditions.

Future Outlook

This filing is an update on beneficial ownership and does not contain forward-looking statements or guidance regarding Repligen Corp.'s future performance.

Management Comments

• T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

Industry Context

StockSavvy.ai notes that this filing is a routine disclosure for institutional investors and reflects ongoing asset management activities within the biotechnology and life sciences sector where Repligen Corp. operates.

Comparison to Industry Standards

• Not Applicable as this filing is a Schedule 13G, which reports beneficial ownership and does not contain performance metrics for comparison against industry standards or specific companies.

Stakeholder Impact

• Shareholders: The filing confirms the continued presence of a significant institutional investor, which can be viewed positively for market stability.
• Management: The filing provides transparency regarding major shareholders.

Next Steps

• T. Rowe Price Associates, Inc. will continue to report any changes in its beneficial ownership of Repligen Corp. securities as required by SEC regulations.

Key Dates

Keywords

Repligen Corp, T. Rowe Price Associates, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Adviser